Advertisement

Breast Cancer Research and Treatment

, Volume 169, Issue 3, pp 469–479 | Cite as

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

  • Wolfgang Janni
  • Emilio Alba
  • Thomas Bachelot
  • Sami Diab
  • Miguel Gil-Gil
  • Thaddeus J. Beck
  • Larisa Ryvo
  • Rafael Lopez
  • Michaela Tsai
  • Francisco J. Esteva
  • Pilar Zamora Auñón
  • Zdenek Kral
  • Patrick Ward
  • Paul Richards
  • Timothy J. Pluard
  • Santosh Sutradhar
  • Michelle Miller
  • Mario Campone
Clinical trial

Abstract

Purpose

The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL).

Methods

Postmenopausal women (N = 668) with HR+ , HER2− ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET. Primary end point was PFS; HRQoL was the secondary end point; DoR was exploratory end point and PFS by TFI was post hoc analysis.

Results

Of 501 pts with measurable disease and confirmed complete or partial response, median DoR was 26.7 months (95% CI, 24.0–NR) in the RIB arm versus 18.6 months (95% CI, 14.8–23.1) in the PBO arm. At 8 weeks, more pts in the RIB arm (32%) versus the PBO arm (17%) experienced best percentage change ≥ 60%. The average pain reduction was greater in the RIB arm (26%) versus the PBO arm (15%). PFS benefit was seen with RIB vs PBO, irrespective of TFI.

Conclusion

RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2− ABC.

Keywords

Ribociclib Advanced breast cancer MONALEESA-2 CDK4/6 

Notes

Acknowledgments

We thank the patients who participated in this trial and their families, as well as staff members at individual trial centers who provided support; Avinash Yerramsetti and Amol Hosing (Novartis Healthcare Pvt Ltd) for providing medical editorial assistance with this manuscript. Ribociclib was discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals.

Funding

The study was initiated, funded, and sponsored by Novartis Pharmaceuticals Corporation. The study was designed by the investigators and the sponsor. Design and conduct of the study was undertaken by the sponsor in collaboration with investigators. The study investigators and their respective research teams collected the data; Novartis Pharmaceuticals Corporation compiled the data for summation and analysis. All authors were responsible for data interpretation. The article was prepared by Dr Janni in conjunction with all the authors, including employees of the sponsor. The corresponding author had final responsibility for the decision to submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

Dr. Janni reports grants and personal fees from Novartis during the conduct of the study and outside the submitted work. Dr. Alba reports advisory board fees from Roche, Pfizer, and Novartis outside the submitted work. Dr. Bachelot reports personal fees from AstraZeneca, Roche, Novartis, and Pfizer; research grants from Roche, Novartis, and Pfizer outside the submitted work. Dr. Esteva reports consulting fee and research funding to his institution. Dr. Pluard reports advisory board fees from Novartis. Mr. Sutradhar is an employee of Novartis Pharmaceutical Corporation. Dr. Miller is employee of Novartis Pharmaceutical Corporation and hold Novartis stock options. Prof. Campone reports fees for advisory boards from Novartis, during the conduct of the study; and fees for advisory boards from Lilly, Sanofi, Pfizer, and AstraZeneca outside the submitted work. Dr. Diab, Dr. Gil, Dr. Beck, Ryvo, Dr. Tsai, Dr. Aunon, Dr. Kral, Dr. Ward, and Dr. Richards have nothing to disclose.

References

  1. 1.
    Gnant M (2012) The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. Curr Oncol Rep 15:14–23.  https://doi.org/10.1007/s11912-012-0277-1 CrossRefGoogle Scholar
  2. 2.
    Gnant M (2012) Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther 12:1579–1589.  https://doi.org/10.1586/era.12.138 CrossRefPubMedGoogle Scholar
  3. 3.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer B (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888.  https://doi.org/10.1093/annonc/mdu385 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Breast Cancer version 2.2017Google Scholar
  5. 5.
    Fox EM, Arteaga CL, Miller TW (2012) Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front Oncol 2:145.  https://doi.org/10.3389/fonc.2012.00145 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247.  https://doi.org/10.1146/annurev-med-070909-182917 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mayer IA, Arteaga CL (2016) The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 67:11–28.  https://doi.org/10.1146/annurev-med-062913-051343 CrossRefPubMedGoogle Scholar
  8. 8.
    Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1:338–351.  https://doi.org/10.1158/2159-8290.CD-11-0101 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70.  https://doi.org/10.1038/nature11412 CrossRefGoogle Scholar
  10. 10.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439.  https://doi.org/10.1016/s1470-2045(15)00613-0 CrossRefPubMedGoogle Scholar
  11. 11.
    Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35.  https://doi.org/10.1016/s1470-2045(14)71159-3 CrossRefPubMedGoogle Scholar
  12. 12.
    Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randolph S, Diéras V, Slamon DJ (2016) PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2− advanced breast cancer (ABC). J Clin Oncol 34:507.  https://doi.org/10.1200/JCO.2016.34.15_suppl.507 CrossRefGoogle Scholar
  13. 13.
    Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M (2015) Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373:209–219.  https://doi.org/10.1056/nejmoa1505270 CrossRefPubMedGoogle Scholar
  14. 14.
    Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, Parasuraman S, Howard S, Keen N, Sellers W, Brain C (2013) Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6− reactivating Rb in cancer. Molecular Cancer Therapeutics 12:PR02-PR02.  https://doi.org/10.1158/1535-7163.targ-13-pr02
  15. 15.
    O’Brien NA, Tomaso ED, Ayala R, Tong L, Issakhanian S, Linnartz R, Finn RS, Hirawat S, Slamon DJ (2014) Abstract 4756: in vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res 74:4756.  https://doi.org/10.1158/1538-7445.am2014-4756 CrossRefGoogle Scholar
  16. 16.
    Juric D, Munster PN, Campone M, Ismail-Khan R, García-Estevez L, Hamilton EP, Becerra C, Boer RHD, Hui R, Goncalves A, Wang Y, Dhuria SV, Kalimi GH, Lorenc KCR, Mayer IA (2016) Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis. J Clin Oncol 34:568.  https://doi.org/10.1200/JCO.2016.34.15_suppl.568 CrossRefGoogle Scholar
  17. 17.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748.  https://doi.org/10.1056/NEJMoa1609709 CrossRefPubMedGoogle Scholar
  18. 18.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte PF, Arteaga CL, Cameron DA, Xuan F, Miller MK, Germa C, Hirawat S, O’Shaughnessy J (2017) Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC). J Clin Oncol 35:1038.  https://doi.org/10.1200/JCO.2017.35.15_suppl.1038 CrossRefGoogle Scholar
  19. 19.
    Nahleh ZA (2008) Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol.  https://doi.org/10.3747/co.v15i6.242 PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Gregorc V, Ghio D, Sallemi C, Bulotta A, Rossoni G, Viganò MG, Fontana F, Rossoni G, Colombi S, Lambiase A, Bordignon C (2015) Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC. J Clin Oncol 33:7557.  https://doi.org/10.1200/jco.2015.33.15_suppl.7557 CrossRefGoogle Scholar
  21. 21.
    Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol.  https://doi.org/10.1200/jco.2017.75.6155 CrossRefPubMedGoogle Scholar
  22. 22.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247.  https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMedGoogle Scholar
  23. 23.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144.  https://doi.org/10.1200/jco.1998.16.1.139 CrossRefPubMedGoogle Scholar
  24. 24.
    Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Manson S, Sutradhar SC, Monaco M, Janni W (2017) Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. J Clin Oncol 35:1020.  https://doi.org/10.1200/JCO.2017.35.15_suppl.1020 CrossRefGoogle Scholar
  25. 25.
    Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and Letrozole in advanced breast cancer. N Engl J Med 375:1925–1936.  https://doi.org/10.1056/NEJMoa1607303 CrossRefPubMedGoogle Scholar
  26. 26.
    Tate SC, Andre V, Enas N, Ribba B, Gueorguieva I (2016) Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer. Eur J Cancer 66:95–103.  https://doi.org/10.1016/j.ejca.2016.07.009 CrossRefPubMedGoogle Scholar
  27. 27.
    Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S (2016) Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 27:1047–1054.  https://doi.org/10.1093/annonc/mdw139 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Boye M, Houghton K, Stull DE, Ainsworth C, Price GL (2017) Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1. J Clin Oncol 35:1060.  https://doi.org/10.1200/JCO.2017.35.15_suppl.1060 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Wolfgang Janni
    • 1
  • Emilio Alba
    • 2
  • Thomas Bachelot
    • 3
  • Sami Diab
    • 4
  • Miguel Gil-Gil
    • 5
  • Thaddeus J. Beck
    • 6
  • Larisa Ryvo
    • 7
  • Rafael Lopez
    • 8
  • Michaela Tsai
    • 9
  • Francisco J. Esteva
    • 10
  • Pilar Zamora Auñón
    • 11
  • Zdenek Kral
    • 12
  • Patrick Ward
    • 13
  • Paul Richards
    • 14
  • Timothy J. Pluard
    • 15
  • Santosh Sutradhar
    • 16
  • Michelle Miller
    • 16
  • Mario Campone
    • 17
  1. 1.University of UlmUlmGermany
  2. 2.Hospital Universitario Virgen de la Victoria, IBIMAMálagaSpain
  3. 3.Centre Léon BérardLyonFrance
  4. 4.Rocky Mountain Cancer CentersAuroraUSA
  5. 5.Institut Català d’Oncologia, IDIBELL, L’Hospitalet de LlobregatBarcelonaSpain
  6. 6.Highlands Oncology GroupFayettevilleUSA
  7. 7.Tel Aviv Sourasky Medical CenterTel AvivIsrael
  8. 8.Hospital Clínico Universitario e Instituto de Investigación Santiago-CIBERONCA CoruñaSpain
  9. 9.Minnesota OncologyMinneapolisUSA
  10. 10.Perlmutter Cancer Center at New York University Langone HealthNew YorkUSA
  11. 11.Hospital Universitario La PazMadridSpain
  12. 12.Department of Internal Medicine, Hematology and OncologyUniversity Hospital BrnoBrnoCzech Republic
  13. 13.Oncology Hematology CareKenwoodUSA
  14. 14.Oncology Hematology Associates of Southwest VirginiaRoanokeUSA
  15. 15.Saint Luke’s Health SystemKansas CityUSA
  16. 16.Novartis Pharmaceuticals CorporationEast HanoverUSA
  17. 17.Centre René Gauducheau, Institut de Cancérologie de l’OuestSaint-HerblainFrance

Personalised recommendations